USFDA approves two generic medications from Zydus
On Saturday, Zydus Lifesciences said that the US health agency has given the company permission to distribute Silodosin capsules in the US for the treatment of benign prostatic hyperplasia. The US Food and Drug Administration (USFDA) has also given the business final approval to market Pregabalin capsules in various strengths, according to a statement from the Ahmedabad-based pharmaceutical company. The indication for silodosin capsules, commonly known as benign prostate enlargement, is to treat the signs and symptoms of an enlarged prostate gland (benign prostatic hyperplasia or BPH). Pregabalin capsules are recommended for treating shingles (herpes zoster) infection and discomfort brought…